Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will present and host investor meetings at multiple January investor conferences, including the Sachs Associates 9th Annual Neuroscience Innovation Forum and Biotech Showcase 2026, both held in San Francisco. President and Chief Executive Officer Seth Lederman, M.D., is scheduled to deliver a company presentation and participate in a panel discussion focused on neuropsychiatric drug development at the Sachs Associates forum, and to present at Biotech Showcase 2026, with a replay of the presentation expected to be made available on the company's website following the event.
This investor outreach comes as Tonix markets FDA-approved TONMYA(TM), a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. TONMYA is the first new prescription medicine approved by the FDA for fibromyalgia in more than 15 years. The company also markets two treatments for acute migraine in adults: Zembrace(R) SymTouch(R) (sumatriptan injection) and Tosymra(R) (sumatriptan nasal spray).
Tonix's development portfolio is focused on central nervous system disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL, which was investigated as TONMYA, is being developed to treat acute stress reaction and acute stress disorder under an Investigator-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense. TNX-102 SL is also in development for major depressive disorder.
The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a Phase 2-ready Fc-modified humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix's rare disease portfolio includes TNX-2900, intranasal oxytocin potentiated with magnesium, in development for Prader-Willi syndrome and expected to start a potential pivotal Phase 2 study in 2026.
Tonix's infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a Phase 2-ready long-acting humanized monoclonal antibody for the seasonal prevention of Lyme disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD's Defense Threat Reduction Agency for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of high lethality infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.
The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. For more information about InvestorWire, please visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer.
